Back to Search
Start Over
Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT
- Source :
- Bone marrow transplantation, 57(4), 562-571. Nature Publishing Group, Bone Marrow Transplantation, Bone Marrow Transplantation, 2022, ⟨10.1038/s41409-022-01577-x⟩
- Publication Year :
- 2022
-
Abstract
- International audience; Whether to choose Haploidentical (Haplo) or one-antigen mismatched unrelated donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PTCy) remains an unanswered question. We compared PTCy- Haplo-HCT to PTCy-1Ag-MMUD-HCT for acute myeloid leukemia (AML) in complete remission (three groups: 1Ag-MMUD using peripheral blood (1Ag-MMUD-PB; n = 155); Haplo using bone marrow (Haplo-BM; n = 647) or peripheral blood (Haplo-PB; n = 949)). Haplo-BM and Haplo-PB had a higher non-relapse mortality (NRM) compared to 1Ag-MMUD-PB (HR 2.28, 95% CI 1.23-4.24, p
- Subjects :
- Cyclophosphamide
Humans
Retrospective Studies
Transplantation Conditioning
Transplantation, Haploidentical
Unrelated Donors
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Leukemia, Myeloid, Acute
Myeloid
endocrine system
Transplantation
Leukemia
Leukemia, Myeloid, Acute/therapy
[SDV.CAN]Life Sciences [q-bio]/Cancer
Hematology
Acute
Haploidentical
Cyclophosphamide/pharmacology
hemic and lymphatic diseases
Acute/therapy
Subjects
Details
- Language :
- English
- ISSN :
- 02683369
- Database :
- OpenAIRE
- Journal :
- Bone marrow transplantation, 57(4), 562-571. Nature Publishing Group, Bone Marrow Transplantation, Bone Marrow Transplantation, 2022, ⟨10.1038/s41409-022-01577-x⟩
- Accession number :
- edsair.doi.dedup.....381e7f1ebdf6e706cdee23d396778f78
- Full Text :
- https://doi.org/10.1038/s41409-022-01577-x⟩